SOPHiA GENETICS SA (SOPH)

Market Cap	212.60M
Revenue (ttm)	64.49M
Net Income (ttm)	-71.40M
Shares Out	66.44M
EPS (ttm)	-1.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,617
Open	3.200
Previous Close	3.130
Day's Range	3.170 - 3.220
52-Week Range	2.700 - 7.370
Beta	1.03
Analysts	Strong Buy
Price Target	7.00 (+118.75%)
Earnings Date	Nov 5, 2024

About SOPH

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, Nor...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Jul 23, 2021
• Employees: 430
• Stock Exchange: NASDAQ
• Ticker Symbol: SOPH
• Website: https://www.sophiagenetics.com

Financial Performance

In 2023, SOPHiA GENETICS's revenue was $62.37 million, an increase of 31.14% compared to the previous year's $47.56 million. Losses were -$78.98 million, -9.68% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for SOPH stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 118.75% from the latest price.

Price Target

$7.0

(118.75% upside)

Analyst Consensus: Strong Buy